RIDDLE&CODE
31.5.2022 10:17:11 CEST | Business Wire | Press release
RIDDLE&CODE is now a member of the Catena-X Automotive Network e.V, an automotive association formed by leading industry players. Both Catena-X and RIDDLE&CODE aim to establish a decentralised data ecosystem through tokenization, tamper-proof identities, and digital twins of machines, vehicles and their components.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005104/en/
Catena-X is dedicated to developing an open, scalable industrial ecosystem that provides a data space and secure processes for all contributors across the automotive industry. The idea is to create a network where manufacturers, suppliers and all those involved in the value chain can participate in creating consistent means for data sharing and standardisation.
About the Catena-X Automotive Network
The Catena-X ecosystem consists of a consortium of 28 members from the automotive, business and scientific communities. It is funded by the German Ministry of Economic Affairs and Climate Action 0. The automotive industry launched a Public Association in 2021, which includes companies that actively want to shape the Catena-X ecosystem l. RIDDLE&CODE has become a member of the Association.
The strategic goal of Catena-X is to implement a standardised ecosystem across the automotive industry. This incentive was initiated by German companies in the automotive sector. It will then be adopted by the entirety of the European automobile industry and beyond.
While the Gaia-X infrastructure initiative aims to provide sovereign access to data via shared services for various industries, Catena-X specifically caters to the automotive industry. Data monetisation and implementation of token-based ecosystems are essential parts of the project. This has been done to drive these industry segments in the right direction of the environmental, social and governance (ESG) goals on different levels.
RIDDLE&CODE’s reasons to join
RIDDLE&CODE will contribute to the Catena-X network by bringing in its expertise in blockchain frameworks. This has been demonstrated through projects such as the European Blockchain Services Infrastructure PCP. RIDDLE&CODE, along with other partners, introduced a truly European architecture dubbed ZENBRIDGE. The project is supported by the European Commission.
Our ambition is to accelerate the move towards a transparent automotive ecosystem where data can be shared easily without facing obstacles from different proprietary infrastructures. Since its inception, RIDDLE&CODE has tackled these challenges.
"We are joining the association and partners to add our Trusted Car Wallet and Distributed Ledger Technology (DLT) software stack to the upcoming connected car data standards," said Minh Cao, Director of Mobility & Automotive at RIDDLE&CODE. "Our focus is to guarantee robust data directly from vehicles, providing trust and transparency to enable automation driven by AI and confidential edge computing."
"The objective is,” he continued, “to build a professional, standardised and modular toolchain for original equipment manufacturers (OEM) developers in the automotive ACES (Automated, Connected, Electric and Shared) and micromobility space that enables rapid prototyping of blockchain-based mobility solutions that leverage cryptographic techniques for data attestation and integration: tokenomics, decentralised data markets & data-rich vehicle networks. The RIDDLE&CODE toolchain will reduce complexity and simplify experimentation so that users can focus on building value-added business models whilst protecting manufacturers' intellectual property (IP)."
Catena-X includes major market shareholders such as BMW AG, Deutsche Telekom AG, Robert Bosch GmbH, Siemens AG, Mercedes-Benz AG and many more. Our membership will include exchanging ideas and technologies to further enrich this initiative.
About RIDDLE&CODE
RIDDLE&CODE is Europe’s leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About the Catena-X Automotive Network
Catena-X sees itself as a rapidly scalable, interoperable ecosystem in which all contributors in the automotive value chain can participate equally. The goal: to provide room for the creation, operation and collaborative use of end-to-end data chains along the entire automotive value chain. As of May 1st 2022, the Catena-X Automotive Network e.V. has 96 members who are active as providers and users in the automotive value chain and cover a wide range of company sizes.
More information: www.catena-x.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005104/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom